Trial Profile
A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PATRIOT
- 06 Oct 2023 Planned number of patients changed from 150 to 87.
- 06 Oct 2023 Planned End Date changed from 1 Dec 2020 to 30 Dec 2023.
- 06 Oct 2023 Planned primary completion date changed from 30 Sep 2020 to 30 Dec 2023.